The approved drugs or drugs under development are poorly water-soluble, so one of the characteristics to improve the drug efficiency, permeability, and bioavailability is enhancing drug hydrophilicity
[85,88][15][18]. For instance, manipulating drug formulation may increase the solubility and dissolution rate of BCS class II (Biopharmaceutics Classification System II) substances in gastrointestinal fluids, increasing bioavailability
[85,89][15][22]. The efficiency of poorly water-soluble drugs can be improved by modifying API dosage, novel drug administration routes, and adopting a suitable combination of active ingredients
[85,88][15][18]. One strategy is to form API dispersion inside a biocompatible polymer matrix or search for alternative solvents
[81,84][19][14]. In this regard, ionic liquids have been utilized as a suitable solvent system for API, owing to the unique physicochemical properties of IL
[85,86,87,88][15][16][17][18]. A suitable cation–anion combination can be made to synthesize numerous ILs
[85][15] with appropriate physical properties desirable for the dissolution/loading of APIs
[85][15]. However, ILs still suffer from biodegradability or toxicity limitations
[85][15]. So, a search for a new biocompatible solvent system with negligible toxicity for API dissolution or solubility is required to improve and develop drug formulations
[85,88][15][18].
One such biocompatible, cheap, less toxic solvent being studied is based on DESs
[85,88,89][15][18][22]. DESs have been used for the dissolution of API, and DESs are prepared using pharmaceuticals as one of the components. So, the following section describes these two applications of DESs.